Medical - Healthcare Plans
Compare Stocks
2 / 10Stock Comparison
CLOV vs UNH
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
CLOV vs UNH — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Healthcare Plans | Medical - Healthcare Plans |
| Market Cap | $1.37B | $333.37B |
| Revenue (TTM) | $2.21B | $449.71B |
| Net Income (TTM) | $-57M | $12.04B |
| Gross Margin | 42.5% | 18.8% |
| Operating Margin | -2.6% | 4.2% |
| Forward P/E | 62.6x | 20.1x |
| Total Debt | $0.00 | $78.39B |
| Cash & Equiv. | $78M | $24.36B |
CLOV vs UNH — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 20 | May 26 | Return |
|---|---|---|---|
| Clover Health Inves… (CLOV) | 100 | 24.0 | -76.0% |
| UnitedHealth Group … (UNH) | 100 | 124.5 | +24.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CLOV vs UNH
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CLOV is the clearest fit if your priority is growth exposure.
- Rev growth 40.3%, EPS growth -93.6%, 3Y rev CAGR 20.6%
- 40.3% revenue growth vs UNH's 11.8%
UNH carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 25 yrs, beta 0.59, yield 2.4%
- 220.3% 10Y total return vs CLOV's -73.7%
- Lower volatility, beta 0.59, Low D/E 77.1%, current ratio 0.79x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 40.3% revenue growth vs UNH's 11.8% | |
| Value | Lower P/E (20.1x vs 62.6x) | |
| Quality / Margins | Combined ratio 1.0 vs CLOV's 1.0 (lower = better underwriting) | |
| Stability / Safety | Beta 0.59 vs CLOV's 1.22 | |
| Dividends | 2.4% yield; 25-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | -4.7% vs CLOV's -20.0% | |
| Efficiency (ROA) | 3.9% ROA vs CLOV's -9.6%, ROIC 9.2% vs -34.0% |
CLOV vs UNH — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
CLOV vs UNH — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
UNH leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
UNH is the larger business by revenue, generating $449.7B annually — 203.4x CLOV's $2.2B. UNH is the more profitable business, keeping 2.7% of every revenue dollar as net income compared to CLOV's -2.6%. On growth, CLOV holds the edge at +62.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $2.2B | $449.7B |
| EBITDAEarnings before interest/tax | -$55M | $23.2B |
| Net IncomeAfter-tax profit | -$57M | $12.0B |
| Free Cash FlowCash after capex | $55M | $19.7B |
| Gross MarginGross profit ÷ Revenue | +42.5% | +18.8% |
| Operating MarginEBIT ÷ Revenue | -2.6% | +4.2% |
| Net MarginNet income ÷ Revenue | -2.6% | +2.7% |
| FCF MarginFCF ÷ Revenue | +2.5% | +4.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +62.0% | +2.0% |
| EPS Growth (YoY)Latest quarter vs prior year | — | +0.7% |
Valuation Metrics
Evenly matched — CLOV and UNH each lead in 2 of 4 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $1.4B | $333.4B |
| Enterprise ValueMkt cap + debt − cash | $1.3B | $387.4B |
| Trailing P/EPrice ÷ TTM EPS | -15.76x | 27.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 62.62x | 20.06x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 16.61x |
| Price / SalesMarket cap ÷ Revenue | 0.71x | 0.74x |
| Price / BookPrice ÷ Book value/share | 4.49x | 3.29x |
| Price / FCFMarket cap ÷ FCF | — | 20.74x |
Profitability & Efficiency
UNH leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
UNH delivers a 11.5% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $-17 for CLOV. On the Piotroski fundamental quality scale (0–9), UNH scores 6/9 vs CLOV's 2/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -17.1% | +11.5% |
| ROA (TTM)Return on assets | -9.6% | +3.9% |
| ROICReturn on invested capital | -34.0% | +9.2% |
| ROCEReturn on capital employed | -24.5% | +9.7% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 6 |
| Debt / EquityFinancial leverage | — | 0.77x |
| Net DebtTotal debt minus cash | -$78M | $54.0B |
| Cash & Equiv.Liquid assets | $78M | $24.4B |
| Total DebtShort + long-term debt | $0 | $78.4B |
| Interest CoverageEBIT ÷ Interest expense | — | 4.71x |
Total Returns (Dividends Reinvested)
Evenly matched — CLOV and UNH each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in UNH five years ago would be worth $9,746 today (with dividends reinvested), compared to $3,256 for CLOV. Over the past 12 months, UNH leads with a -4.7% total return vs CLOV's -20.0%. The 3-year compound annual growth rate (CAGR) favors CLOV at 45.1% vs UNH's -7.3% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +11.2% | +9.8% |
| 1-Year ReturnPast 12 months | -20.0% | -4.7% |
| 3-Year ReturnCumulative with dividends | +205.7% | -20.4% |
| 5-Year ReturnCumulative with dividends | -67.4% | -2.5% |
| 10-Year ReturnCumulative with dividends | -73.7% | +220.3% |
| CAGR (3Y)Annualised 3-year return | +45.1% | -7.3% |
Risk & Volatility
UNH leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
UNH is the less volatile stock with a 0.59 beta — it tends to amplify market swings less than CLOV's 1.22 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. UNH currently trades 90.7% from its 52-week high vs CLOV's 68.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.22x | 0.59x |
| 52-Week HighHighest price in past year | $3.92 | $404.72 |
| 52-Week LowLowest price in past year | $1.58 | $234.60 |
| % of 52W HighCurrent price vs 52-week peak | +68.4% | +90.7% |
| RSI (14)Momentum oscillator 0–100 | 67.0 | 74.5 |
| Avg Volume (50D)Average daily shares traded | 5.6M | 8.1M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates CLOV as "Hold" and UNH as "Buy". Consensus price targets imply 24.3% upside for CLOV (target: $3) vs 4.9% for UNH (target: $385). UNH is the only dividend payer here at 2.37% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $3.33 | $385.43 |
| # AnalystsCovering analysts | 9 | 52 |
| Dividend YieldAnnual dividend ÷ price | — | +2.4% |
| Dividend StreakConsecutive years of raises | — | 25 |
| Dividend / ShareAnnual DPS | — | $8.70 |
| Buyback YieldShare repurchases ÷ mkt cap | +4.0% | +1.7% |
UNH leads in 3 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 2 categories are tied.
CLOV vs UNH: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is CLOV or UNH a better buy right now?
For growth investors, Clover Health Investments, Corp.
(CLOV) is the stronger pick with 40. 3% revenue growth year-over-year, versus 11. 8% for UnitedHealth Group Incorporated (UNH). UnitedHealth Group Incorporated (UNH) offers the better valuation at 27. 8x trailing P/E (20. 1x forward), making it the more compelling value choice. Analysts rate UnitedHealth Group Incorporated (UNH) a "Buy" — based on 52 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CLOV or UNH?
On forward P/E, UnitedHealth Group Incorporated is actually cheaper at 20.
1x.
03Which is the better long-term investment — CLOV or UNH?
Over the past 5 years, UnitedHealth Group Incorporated (UNH) delivered a total return of -2.
5%, compared to -67. 4% for Clover Health Investments, Corp. (CLOV). Over 10 years, the gap is even starker: UNH returned +220. 3% versus CLOV's -73. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CLOV or UNH?
By beta (market sensitivity over 5 years), UnitedHealth Group Incorporated (UNH) is the lower-risk stock at 0.
59β versus Clover Health Investments, Corp. 's 1. 22β — meaning CLOV is approximately 108% more volatile than UNH relative to the S&P 500.
05Which is growing faster — CLOV or UNH?
By revenue growth (latest reported year), Clover Health Investments, Corp.
(CLOV) is pulling ahead at 40. 3% versus 11. 8% for UnitedHealth Group Incorporated (UNH). On earnings-per-share growth, the picture is similar: UnitedHealth Group Incorporated grew EPS -14. 7% year-over-year, compared to -93. 6% for Clover Health Investments, Corp.. Over a 3-year CAGR, CLOV leads at 20. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CLOV or UNH?
UnitedHealth Group Incorporated (UNH) is the more profitable company, earning 2.
7% net margin versus -4. 4% for Clover Health Investments, Corp. — meaning it keeps 2. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UNH leads at 4. 2% versus -4. 4% for CLOV. At the gross margin level — before operating expenses — UNH leads at 18. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CLOV or UNH more undervalued right now?
On forward earnings alone, UnitedHealth Group Incorporated (UNH) trades at 20.
1x forward P/E versus 62. 6x for Clover Health Investments, Corp. — 42. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CLOV: 24. 3% to $3. 33.
08Which pays a better dividend — CLOV or UNH?
In this comparison, UNH (2.
4% yield) pays a dividend. CLOV does not pay a meaningful dividend and should not be held primarily for income.
09Is CLOV or UNH better for a retirement portfolio?
For long-horizon retirement investors, UnitedHealth Group Incorporated (UNH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
59), 2. 4% yield, +220. 3% 10Y return). Both have compounded well over 10 years (UNH: +220. 3%, CLOV: -73. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CLOV and UNH?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CLOV is a small-cap high-growth stock; UNH is a large-cap quality compounder stock. UNH pays a dividend while CLOV does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.